Brief: Regulus Therapeutics Says First Patient Dosed In Second Cohort Of Phase 1b MAD Clinical Trial Of RGLS8429
27/06/2023 14:55
June 27 (Reuters) - Regulus Therapeutics Inc RGLS.O :
* REGULUS THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN
SECOND
COHORT OF PHASE 1B MULTIPLE-ASCENDING DOSE (MAD) CLINICAL TRIAL
OF RGLS8429 FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC
KIDNEY DISEASE (ADPKD)
* REGULUS THERAPEUTICS INC - ON TRACK TO DELIVER TOPLINE
DATA FROM
FIRST COHORT AROUND END OF Q3 OF THIS YEAR
Source text for Eikon: ID:nPn8PKkM0a
Further company coverage: RGLS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regulus Therapeutics
See all newsBrief: Novartis Completes Acquisition Of Regulus Therapeutics
Brief: Novartis Announces Expiration Of Hart-Scott-Rodino Waiting Period Of Regulus Therapeutics Tender Offer
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Regulus Therapeutics
Regulus Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Regulus Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview